A Phase I Study of Neoadjuvant Capecitabine, Oxaliplatin, and Irinotecan (XELOXIRI) in Patients with Locally Advanced Rectal Cancer
Conclusions: XELOXIRI is a feasible and active regimen for patients with locally advanced rectal cancer. Febrile neutropenia was the DLT, and the RD of irinotecan is 150 mg/m2.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Eating Disorders & Weight Management | Eloxatin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Rectal Cancers | Study | Toxicology | Xeloda